MTF Biologics expanded its strategic agreement with Kolosis BIO. Kolosis has grown the portfolio of MTF Biologics allograft solutions it represents and distributes to include DBX Mix and DBX Putty.
Kolosis exclusively partners with MTF Biologics to offer bone graft technologies such as Kore Fiber, a 100% demineralized cortical bone allograft; Prime HD, a pre-hydrated DBM; and now DBX. These allografts are backed by MTF Biologics’ proprietary aseptic processing methods that optimally preserve matrix structures and osteoinductive properties.
“Kolosis has been a great collaborator for MTF Biologics for many years, and we share a dedication to delivering the highest-quality allograft solutions, while improving patient care and expanding the gift of donation,” said Brad Bailey, Vice President and General Manager of MTF Biologics’ Orthopedic Franchise. “We are excited to expand our partnership to include the DBX family of allograft tissues, which are used in many types of orthopedic surgery to help address a variety of challenges from spinal and joint fusion to non-healing fractures.”
“We are honored to welcome the DBX brand into our expanding portfolio of bone graft solutions,” said Collin Begley, CEO of Kolosis BIO. “With a 20-year legacy in the premium DBM category, DBX deserves the focus and dedication Kolosis will bring. We are excited to introduce it to new surgeons through our proven commercial team and sales channel.”
MTF Biologics expanded its strategic agreement with Kolosis BIO. Kolosis has grown the portfolio of MTF Biologics allograft solutions it represents and distributes to include DBX Mix and DBX Putty.
Kolosis exclusively partners with MTF Biologics to offer bone graft technologies such as Kore Fiber, a 100% demineralized cortical bone...
MTF Biologics expanded its strategic agreement with Kolosis BIO. Kolosis has grown the portfolio of MTF Biologics allograft solutions it represents and distributes to include DBX Mix and DBX Putty.
Kolosis exclusively partners with MTF Biologics to offer bone graft technologies such as Kore Fiber, a 100% demineralized cortical bone allograft; Prime HD, a pre-hydrated DBM; and now DBX. These allografts are backed by MTF Biologics’ proprietary aseptic processing methods that optimally preserve matrix structures and osteoinductive properties.
“Kolosis has been a great collaborator for MTF Biologics for many years, and we share a dedication to delivering the highest-quality allograft solutions, while improving patient care and expanding the gift of donation,” said Brad Bailey, Vice President and General Manager of MTF Biologics’ Orthopedic Franchise. “We are excited to expand our partnership to include the DBX family of allograft tissues, which are used in many types of orthopedic surgery to help address a variety of challenges from spinal and joint fusion to non-healing fractures.”
“We are honored to welcome the DBX brand into our expanding portfolio of bone graft solutions,” said Collin Begley, CEO of Kolosis BIO. “With a 20-year legacy in the premium DBM category, DBX deserves the focus and dedication Kolosis will bring. We are excited to introduce it to new surgeons through our proven commercial team and sales channel.”
Copy to clipboard 
